Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

Clinical trial NCT07085767 · RECRUITING

Trial details

NCT number: NCT07085767
Sponsor: Olema Pharmaceuticals, Inc.
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Breast Cancer Locally Advanced Breast Cancer Metastatic Breast Cancer ER Positive Breast Cancer HER2 Negative Breast Carcinoma

Start date: 2025-11-03
Primary completion: 2028-12-01
Enrollment: 1000

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.